AI assistant
ABIONYX Pharma Board/Management Information 2019
1062_iss_2019-09-13_9dbd6e5b-8d30-4ba5-9d15-67a357df8881.pdf
Board/Management Information
Open in viewerOpens in your device viewer
Press Release
Message from the Board of Directors
Toulouse, FRANCE, Lakeland, UNITED-STATES, September 13, 2019, 8:00am CEST – ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) today announced that the Board of Directors has taken note of the resignation of its current Chairman, Mr. Richard Pasternak, as Director and Chairman of the Board.
The Board elected Mr. Emmanuel Huynh as Chairman of the Board and confirmed Mr. Cyrille Tupin as Chief Executive Officer. The Board expresses its confidence in its new Chairman and in its Chief Executive Officer and assures them of its full support in their mission.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in immuno-oncology and chemotherapy.
Contacts
NewCap Investor relations Louis-Victor Delouvrier [email protected] +33 (0)1 44 71 98 53
NewCap Media relations Nicolas Merigeau [email protected] +33 (0)1 44 71 94 98